Kidney Week

Abstract: FR-PO300

Association Between Use of Proton Pump Inhibitors and Hypomagnesemia: A Meta-Analysis

Session Information

• Fluid and Electrolytes: Clinical
  October 26, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Fluid and Electrolytes

• 902 Fluid and Electrolytes: Clinical

Authors

• Susantitaphong, Paweena, Chulalongkorn University, Bangkok, Thailand

Paweena Susantitaphong,

• Srinutta, Thawin, Chulalongkorn University, Bangkok, Thailand

Thawin Srinutta,

• Chewcharat, Api, Chulalongkorn University, Bangkok, Thailand

Api Chewcharat,

• Takkavatakarn, Kullaya, Division of Nephrology, King Chulalongkorn Memorial hospital, Bangkok, Thailand

Kullaya Takkavatakarn,

• Praditpornsilpa, Kearkiat, Chulalongkorn University, Bangkok, Thailand

Kearkiat Praditpornsilpa,

• Jaber, Bertrand L., St. Elizabeth's Medical Center, Boston, Massachusetts, United States

Bertrand L. Jaber,

• Eiam-Ong, Somchai, Chulalongkorn University, Bangkok, Thailand

Somchai Eiam-Ong,

Background

Hypomagnesemia is associated with an increased risk of cardiac arrhythmia and mortality. The use of proton pump inhibitors (PPIs) has been inconsistently associated with development of hypomagnesemia. To shed more light on this controversy, we performed a meta-analysis to examine the association between use of PPIs and hypomagnesemia.

Methods

The literature search was conducted in MEDLINE, Scopus, and Cochrane Central Register of Controlled Trials (through December 2017) to identify observational studies that examined the association between use of PPIs and development of hypomagnesemia. Random-effects model meta-analysis was used to compute the pooled odds ratio (OR) with 95% confidence interval (CI).

Results

Thirteen cohort studies were identified, totaling 125,280 patients. 38.7% (95% CI 29.5-48.7%) of patients were PPI users. The baseline prevalence of diabetes mellitus and diuretic use was not significantly different between PPI users and non-users. By meta-analysis, use of PPIs was associated with a higher odds for development of hypomagnesemia (pooled odds ratio 1.83; 95% CI 1.26, 2.67; P = 0.002; I² = 97%).

Conclusion

The use of PPIs is significantly associated with development of hypomagnesemia. As a result, serum magnesium levels should be monitored in patients receiving long-term PPIs.